GSK plc

CIK 0001131399 · LONDON, null · Quarter end: 2026-06-30 · Filed on: 2026-08-13 · Open the SEC source

GSK plc reported 13 positions worth $602.2M as of June 30, 2026 (13F filed August 13, 2026). Largest holding: CRSP (29.2%).

Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$602.2M
2026 Q2
Positions
13
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
97.5%
Est. Net Flow (Q)
2026 Q2
10 / 13 positions shown
#SymbolCompanyTypeValue% Port.Shares1YYTD
1CRSPCRISPR THERAPEUTICS AGSH$175.7M29.17%3,220,627
2Y95308105WAVE LIFE SCIENCES LTDSH$106.0M17.60%18,245,691
3VIRVIR BIOTECHNOLOGY INCSH$87.1M14.47%8,550,954
4BNTXBIONTECH SESH$82.8M13.75%889,824
5IDYAIDEAYA BIOSCIENCES INCSH$49.7M8.25%1,333,333
6CYTKCYTOKINETICS INCSH$29.0M4.82%340,434
7LYELLYELL IMMUNOPHARMA INCSH$21.3M3.53%1,512,659
8SPROSPERO THERAPEUTICS INCSH$20.3M3.37%9,190,606
9NKTXNKARTA INCSH$8.9M1.48%3,150,732
10FULCFULCRUM THERAPEUTICS INCSH$6.5M1.09%1,785,714

The free plan shows the top 10 positions. The remaining 3 positions, the full portfolio and quarter changes unlock with Pro.

Pro Feature

This section is exclusive to Fundocap Pro. Full holdings tables, consensus trades, ownership analysis, backtests and exports unlock with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

Frequently Asked Questions

What stocks does GSK plc hold as of Q2 2026?

GSK plc reported 13 positions worth $602.2M in its Q2 2026 13F filing. Largest positions: CRSP (29.2%), WAVE LIFE SCIENCES LTD (17.6%), VIR (14.5%), BNTX (13.7%) and IDYA (8.3%).

What did GSK plc buy in Q2 2026?

No previous quarter is available yet; the comparison appears with the next filing.

What did GSK plc sell in Q2 2026?

No previous quarter is available yet.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.